Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer). With the addition of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, IL and the H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, the Phase II clinical trial is presently being conducted in seven sites. The principal investigator for Northwestern is Mary Mulcahy, MD, and the principal investigator for Lee Moffitt is Larry K. Kvols, M.D.

"The addition of these two major cancer centers to the Phase II trial of Atiprimod in advanced carcinoid patients signifies our continuing commitment to facilitate rapid enrollment of this trial," said Dr. Gary S. Jacob, Chief Executive Officer of Callisto. "Both sites are active in the treatment of neuroendocrine cancers, and have built significant reputations within the carcinoid community, which should substantially enhance the pace of enrollment and increased accessibility to prospective patients interested in participating in this trial." Currently Callisto has enrolled 31 patients of the 40 subjects planned for this Phase II clinical trial.

The primary objective of the Phase II clinical trial is to evaluate efficacy of Atiprimod in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy (octreotide). Patients, after signing an informed consent, are required to complete two weeks of a symptoms diary to establish their symptoms baseline before commencing Atiprimod dosing. A maximum of 40 evaluable patients will be enrolled in th
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 DUSA Pharmaceuticals...mpany that is developing and marketing Levulan(... focused on patients with common skin conditions, ...utive Officer, will present a corporate overview a... Tuesday, November 10, 2009 at 10:00 a.m. ET at th...
(Date:11/6/2009)... Repossessions and liquidations of... quarter of 2009 declined as compared to similar f...ment,s NasTrac Quarterly Index (NQI). The figures...oth repossessions and orderly liquidations, also i...tion and printing equipment, offering mixed news o...
(Date:11/6/2009)...Newswire-USNewswire/ -- America,s Specialty Medici... mid-market and smaller innovator pharmaceutical c..., the "Affordable Health Care for America Act," in...smaller companies fear that the cumulative effect ...heir efforts to bring new medicines to market. ,...
Breaking Medicine Technology:NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Hundreds of Genes Could Be Linked to ADHD 50082 1Hundreds of Genes Could Be Linked to ADHD 50082 2Nations first childrens hospital based safety store focuses on child injury prevention 50079 1Nations first childrens hospital based safety store focuses on child injury prevention 50079 2Health care outcome boost needs better studies 50076 1Health care outcome boost needs better studies 50076 2Health care outcome boost needs better studies 50076 3Health care outcome boost needs better studies 50076 4
...Determine Phase 2 Dosing Regimen -, SOUTH SAN FRA...c., a privately held company focused on the develo...or cancer, today announced,updated results from an...inical trial of RAV12, its lead therapeutic antibo...omas. The objectives of the study were to,define t...
...erapy Proven to Significantly Improve Overall Surv...Cancer, WAYNE, N.J. and EMERYVILLE, Calif., Nov. ...maceuticals, Inc. (Nasdaq:,ONXX) today announced t...s,approved a supplemental New Drug Application for...of patients with unresectable hepatocellular,carci...
Other Medicine Technology:Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas 2Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:11/8/2009)...h holds open house at Victoria campus , ...09 -- UCW Academy of Health invites anyone looking...lth care industry to attend their open house in Vi...ademy of Health, which offers diplomas in areas su... designs its programs to meet the needs of the hea...
(Date:11/8/2009)...e/ -- Speaker Nancy Pelosi and Democratic leaders ...e of H.R. 3962, the Affordable Health Care for Ame.... Below are the Speaker,s opening remarks: ,,... from the President of the United States, Barack O... American people. I thank the President for his tr...
(Date:11/8/2009)...is pleased to announce that it has been successful...nd who recently received an award on the $800 mill...ludes not only the Veterans Administration, but al...ncies. , New York, NY (PR...eased to announce that it has been successful in p...
(Date:11/8/2009)...n the Western District of Pennsylvania award a Fay... for a medical malpractice case. Attorneys Thomas...s E. Crenney and Associates, LLC handled the case ...gainst the Uniontown Hospital. The woman had to h...ge 18. , Pittsburgh, PA(P...
(Date:11/8/2009)...alth advocates committed to achieving meaningful h...7 "Tonight the U.S. Hou...oice of America,s families by passing the Affordab...t deliver, without delay, on the promise of meanin..., President and CEO of the National Alliance for H...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2
...e,s Closure to Have Disproportionate Impact On Lat...rved Groups, OAKLAND, Calif., Oct. 25 Sutter Hea...n Francisco will have a particularly,adverse impac...tee. CNA/NNOC presented the data at a San Francisc...
...new way to treat individuals with cancer that is b...nd kill cancer cells while leaving normal cells un...s. In a new study, David Kirn and colleagues at Je...er selecting a highly potent strain of poxvirus th...
...ADELPHIA A new Center for Excellence in Ethical, ...been established at the University of Pennsylvania...ols of Nursing and Arts and Sciences, the Wharton ...over $5 million over the next five years from the ...
...ue allows trapped air a way out, experts say , THU...o treat emphysema patients shows promise, research...uctive pulmonary disease (COPD), is a progressive,...s a minimally invasive, catheter-based bronchoscop...
...ER, Oct. 25 /PRNewswire-FirstCall/ - Biotech Holdi... it has signed an agreement, with,a private compan...ion of,its Sucanon Type II diabetes drug in four C...l population of approximately 33 million people, w...
...IL, Oct. 25 /PRNewswire-FirstCall/ - SXC Health So...that Mr. Gordon S. Glenn, Chairman and,Chief Execu...day, November,8, 2007 at 8:30 a.m. ET to discuss t...y. All interested parties can join the call by di...
Other Medicine News:Health News:CNA Presents New Data on Sutter's Medical Redlining 2Health News:CNA Presents New Data on Sutter's Medical Redlining 3Health News:Penn wins $5M to start center for ethical, legal and social implications research 2Health News:Penn wins $5M to start center for ethical, legal and social implications research 3Health News:SXC Health Solutions to Host Fiscal 2007 Third Quarter Financial Results Conference Call 2
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: